BrainsWay says pilot study shows 83.3% response rate for Deep TMS in depression with early-stage Alzheimer’s

• BrainsWay flagged peer-reviewed pilot-study results already published on Sept. 8, 2026 for Deep TMS in depression with early-stage Alzheimer’s.
• Patients showed meaningful improvement in depressive symptoms, with many reaching remission, supporting further clinical development in this difficult-to-treat group.
• Researchers also reported brain-activity changes consistent with improved network function, adding biological support to the clinical signal.
• Deep TMS is not FDA-cleared for Alzheimer’s disease, placing any expansion into that indication behind additional controlled trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainsway Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080730PRIMZONEFULLFEED9822105) on September 08, 2026, and is solely responsible for the information contained therein.